The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
One woman details her shift in Christmas spending priorities to fund weight-loss injections. Discover how she's saving money on gifts, meals, and outings to maintain her health goals.
Eli Lilly is currently thriving, fueled by the success of its GLP-1 drugs. However, factors such as market competition and the eventual expiration of patent protections pose potential challenges to its long-term growth.
Comedian Amy Schumer has announced her separation from Chris Fischer after seven years of marriage. In an Instagram post, Schumer addressed rumors connecting her recent weight loss to the split, emphasizing that her health journey was unrelated to the separation.
Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
Stephen Nolan, a BBC Radio Ulster and Radio 5 Live presenter, has openly discussed his struggles with weight for many years. Recently, he shared that he's using weight loss injections in addition to diet and exercise. Nolan has already lost a significant amount of weight.
Vikrant Shrotriya of Novo Nordisk India details Ozempic's launch in India, emphasizing stable supply and accessibility. He addresses patent expiry and competition, focusing on broader patient access and combating obesity.
New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.
A new weight loss drug, retatrutide, is showing promise by mimicking three hunger-regulating hormones. Clinical trial data indicates significant weight loss and reduced knee pain.
Mounjaro, a drug by Eli Lilly, is set to be added to China's state health insurance on January 1st. This inclusion could intensify competition among pharmaceutical companies. The move aims to improve access for China's large population.
